Comparison of the 12-Month Outcomes of Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy.
BACKGROUND
To compare the 12-month outcomes of intravitreal ranibizumab (IVR) between two angiographic subtypes of polypoidal choroidal vasculopathy (PCV).


METHODS
This is a retrospective cohort study of 38 treatment-naïve PCV cases. Three consecutive IVR and retreatments as needed were performed. Subsequently, the PCV cases were classified into two phenotypes (18 type 1 and 20 type 2) according to the status of branching vascular network. The best-corrected visual acuity (BCVA) was evaluated in each PCV subtype up to 12 months after the initial IVR.


RESULTS
The mean BCVA was significantly improved from baseline in type 1 PCV while not in type 2 PCV. In type 2 PCV, 3 cases showed severe visual loss after 6 months from the initial IVR. The mean retreatment number was 1.9 ± 1.7 in type 1 PCV and 1.2 ± 1.3 in type 2 PCV.


CONCLUSIONS
The outcomes of IVR may be different between two angiographic subtypes of PCV.
Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Shunichiro
S
Nakai
Shigeru
S
Honda
Akiko
A
Miki
Wataru
W
Matsumiya
Makoto
M
Nakamura
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D002829:Choroid / Q000098:blood supply*; D015862:Choroid Diseases / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography / Q000379:methods*; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D011127:Polyps / Q000175:diagnosis / Q000188:drug therapy*; D000069579:Ranibizumab / Q000008:administration & dosage*; D012189:Retrospective Studies; D013997:Time Factors; D041623:Tomography, Optical Coherence / Q000379:methods; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab